Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Turnstone Biologics Corp. - Common Stock (NQ:TSBX)

0.3527 +0.0204 (+6.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Turnstone Biologics Corp. - Common Stock

< Previous 1 2 Next >
Get insights into the top gainers and losers of Friday's after-hours session.
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
From Brodsky & Smith LLC
Via GlobeNewswire
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps
XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right. 
Via Stocktwits
TSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
From XOMA Royalty Corporation; Turnstone Biologics Corp.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Which stocks have an unusual volume on Wednesday?
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Announces Plans to Explore Strategic Alternatives
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Portfolio Prioritization and Corporate Restructuring Extends Cash Runway into 2Q 2026 
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
From Turnstone Biologics Corp.
Via GlobeNewswire
Crude Oil Gains Over 1%; Alibaba Posts Weak Revenue
Via Benzinga
Nasdaq Jumps Over 2%; Walmart Earnings Top Views
Via Benzinga
Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study
Turnstone Biologics stock drops after Phase 1 STARLING trial data reveals mixed results for TIDAL-01 in metastatic colorectal cancer, with a 25% response rate. 
Via Benzinga
Dow Surges Over 500 Points; US Retail Sales Rise In July
Via Benzinga
Topics Stocks
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today?
Turnstone Biologics stock is down on Thursday as TSBX investors react to the company missing estimates for Q2. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news today! 
Via InvestorPlace
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
TSBX Stock Earnings: Turnstone Biologics Misses EPS for Q2 2024
TSBX stock results show that Turnstone Biologics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
From Turnstone Biologics Corp.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
TSBX Stock Earnings: Turnstone Biologics Misses EPS for Q1 2024
TSBX stock results show that Turnstone Biologics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.